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Abstract: Reacytive Oxygen Species (ROS) have long been considered to be involved in 
the initiation, progression and metastasis of cancer. However, accumulating evidence points 
to the benefical role of ROS. Moreover, ROS production, leading to apoptosis, is the 
mechanism by which many chemotherapeutic agents can act. Beside direct actions, ROS 
elicit lipid peroxidation, leading to the production of 4-hydroxynoneal (HNE). Interestingly, 
HNE also seems to have a dual behaviour with respect to cancer. In this review we present 
recent literature data which outline the "two-faced" character of oxidative stress and lipid 
peroxidation in carcinogenesis and in the hallmarks of cancer. 
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1. Oxidative Stress and Lipid Peroxidation, an Introduction 
Oxidative stress arises from an imbalanced redox status between the production of Reactive Oxygen 
Species (ROS) and the biological system able to remove them. ROS, including superoxide (O2−), 
hydroxyl radical (·OH) and H2O2, are constantly generated in aerobic organisms. The endogenous 
sources usually are oxidative phosphorylation, P450 metabolism, peroxisomes and inflammatory cell 
activation [1,2]. Classically, ROS were regarded as host defending molecules released by the 
neutrophils for destroying exogenous pathogens such as bacteria. ROS can be also produced as a 
consequence of ionizing radiation (IR), chemotherapeutic drugs and environmental exposure to 
transition metals and chemical oxidants [1,3,4]. Cellular antioxidant defense enzymes, against 
oxidative stress, comprise the superoxide dismutases, glutathione peroxidase and catalase [1]. 
Superoxide dismutases and glutathione peroxidases, which are present in cytosol and mitochondria, 
reduce the superoxide anion to hydrogen peroxide and water, and removes the majority of hydrogen 
peroxide, respectively. Meanwhile, catalase, located in peroxisomes, also removes high levels of 
hydrogen peroxide. Nonenzymatic antioxidants, like vitamin E, vitamin C, β-carotene, glutathione, and 
coenzyme Q function to quench ROS [5]. 
ROS can randomly react with lipids, proteins and nucleic acids causing oxidative stress and damage 
in these macromolecules, leading to pathogenesis of age-related and chronic diseases, which include 
cancer, cardiovascular disease, diabetes, chronic inflammation, and neurodegenerative disorders [6–11]. 
Recently, a lot of evidence indicates that ROS play a central role in the key intracellular signal 
transduction pathway for a variety of cellular process [12]. 
When ROS target lipids, they can initiate the lipid peroxidation process, a chain reaction that 
produces multiple breakdown molecules, such as malonaldehyde (MDA) and 4-hydroxyalkenals [13] 
(Scheme 1). 4-Hydroxynonenal (HNE), a 4-hydroxyalkenal, is the most intensively studied  
aldehyde [14]. HNE has three main functional groups: the aldehyde group, the C=C double bond and 
the hydroxyl group, which can participate, alone or in sequence, in chemical reactions with other 
molecules [13]. HNE is a highly electrophilic molecule that easily reacts with low molecular weight 
compounds, such as glutathione, with proteins and, at higher concentration, with DNA and acts as 
mediator of oxidative stress [13,15]. Once formed, HNE is rapidly degraded by three major reactions: 
reduction to 1,4-dihydroxy-2-nonene by alcohol dehydrogenases, oxidation to 4-hydroxy-2-nonenoic 
acid by aldehyde dehydrogenase, or formation of the glutathione-conjugate (GS-HNE) catalyzed by 
glutathione-S-transferases. The majority of HNE is metabolized through forming GS-HNE [16]. The 
half-life of HNE has been studied in several cell types, in subcellular organelles, and even in whole 
organisms [reviewed in 17]. Liver tissue generally has the highest capacity to metabolize HNE. Rat 
hepatocytes (106 cells/mL) were able to metabolize about 90% of 100 µM HNE within 3 min [18]. In 
other cells, the HNE metabolism is not so fast, but still very efficient. For instance when 10 µM HNE 
was added to 106 K562 or HL-60 leukemic cells, the aldehyde disappeared within 1 hour [19]. On the 
basis of such experimental evidence, one can conclude that HNE, even at very high lipid peroxidation 
rates, cannot accumulate in an unlimited manner. 
HNE has been detected in vivo in several pathological conditions, which entail increased lipid 
peroxidation, including inflammation, atherosclerosis, chronic degenerative diseases of the nervous system, 
and chronic liver diseases, reaching a concentration up to about 10 µM [20]. However, under 
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physiological conditions, HNE can be found at low concentrations in human tissues and plasma 
(0.07–2.8 µM) [13,17] where it participates in the control of biological processes, such as signal 
transduction, cell proliferation and differentiation. Indeed, HNE, similarly to ROS, plays an important 
role in controlling the intracellular signal transduction pathways involved in a number of cell  
responses [17,21–23]. 
Scheme 1. Simplified scheme showing ROS and HNE pathways. SOD: superoxide 
dismutase; GPx glutathione peroxidase; CAT: catalase; Vit C: Vitamin C; Vit. E: Vitamin 
E: GSH: Glutathione; MDA: malonildialdehyde; ALDH: aldehyde dehydrogenase; AR, 
aldose reductase; ADH, alcohol dehydrogenase; GST: glutathione S-transferase. 
 
2. ROS and HNE in Carcinogenesis 
Most carcinogens are able to interact with DNA, forming carcinogen-DNA adducts. ROS and HNE 
seem to share this feature and this has been proposed as the mechanism of tumor induction. ROS cause 
oxidative modification of DNA bases resulting in DNA modification and gene mutation, which may be 
all be carcinogenic [24]. Hydroxy radicals, for example, react with guanosine to form 8-hydroxy-
2’deoxyadenosine (8OHdG), which may lead to a G:C to T:A transversion-type point mutation 
contributing, for example to generation of p53 mutations. This is one of the best pieces of evidence 
indicating that oxidative stress is intimately associated with carcinogenesis [25]. In addition to nuclear 
DNA ROS-mediated, mutations in mitochondrial DNA have recently emerged as another important 
target in carcinogenesis [26]. 
However the ROS-induced association with cancer is controversial and it is unlikely that the pro-
carcinogenic effects of ROS are all due to elevated direct oxidative damage to DNA bases, simply 
because there are situations where 8OHdG levels can be elevated, but cancers do not increase [27]. For 
example, patients with rheumatoid arthritis or with type 2 diabetes show elevated 8OHdG levels, but 
Cancers 2010, 2              
 
341 
no clear evidence for a generalized increased cancer has been found [28]. This may suggest that 
oxidative DNA base damage alone is insufficient to cause cancer development or perhaps that damage 
over only a certain range is effective, excessive damage having an anti-cancer effect by promoting 
apoptosis [28]. 
The genotoxic and mutagenic effect of HNE has been demonstrated in both procaryotic and 
eukaryotic cell lines. This strongly alkylating aldehyde is able to directly affect DNA. The genotoxic 
property of HNE was demonstrated, for example, in primary hepatocytes and cerebral microvascular 
endothelial cells, where an increase of micronuclei, chromosomal aberrations and sister chromatid 
exchanges was observed [29]. 
Mutagenicity of HNE has been demonstrated in several experimental settings [30-33]. Possible 
mechanisms for HNE induced mutagenicity are the formation of DNA-adducts with metabolites of 
HNE. Indeed, HNE can be further metabolized to an epoxyde intermediate that interacts with DNA to 
form exocyclin etheno-modified DNA bases [34]. In addition, bulkly exocyclin propane-type DNA 
adducts with guanine, and 6-(1-hydroxyhexanyl)-8-hydroxy-1,N2-propano-2’deoxyguanine (HNE-dG) 
adducts may be formed [35]. 
Etheno-DNA adduct levels were found to be significantly elevated in organs with diseases related to 
a persistent inflammatory process that can lead to malignancies, such as chronic pancreatitis, ulcerative 
colitis, viral Hepatitis B and Crohn’s disease [36]. These authors suggested that the etheno-DNA 
adducts may serve as potential markers for assessing progression of inflammatory cancer-prone 
diseases [36]. 
Formation of DNA lesions by excess ROS and lipid peroxidation end products leads to an increased 
p53 mutation load in non-tumorous liver tissues of Wilson Disease and hemochromatosis patients [37]. 
This study also reported a hot-spot mutation, a G:C versus T:A transversion in codon 249 (-AGG*-). 
Most interestingly, it was shown that in the wild-type p53 cell line, HNE caused a high frequency of 
the same G vs T mutation at codon 249. So, HNE may be involved in etiopathogenesis of human 
cancers having a p53 mutation at codon 249, which is a unique mutational hot-spot in hepatocellular 
carcinomas [38]. In addition to epsilon-adducts, exocyclic 1,N2-propano-2’deoxyguanine adducts 
carrying a hydroxy-hexanyl side chain (HNE-dG) have appeared in HNE-treated cells [39] which seem 
to be involved in inducing mutation on the p53 gene [40]. 
The demonstration of HNE mutagenicity “in vitro” obviously doesn’t assure that this mechanism 
also occurs “in vivo”. Moreover, it is necessary to pay attention to HNE doses employed for such 
studies. Several mutagenic assays with HNE have been performed with high doses of HNE (more than 
100 µM). It seems rather unlikely that HNE or other aldehydes can reach overall concentrations in the 
range of 100 µM in cells and organs [13]. It is conceivable that such levels may be built up locally near 
or within peroxidizing membranes for a short time because of their high lipophilicity. It has been 
calculated, for example, that the concentration of HNE in the lipid bilayer of isolated peroxidizing 
microsomes is about 4.5 mM [41]. Nevertheless, a convincing demonstration that this very high 
concentration can reach into the cells has remained elusive. On the other hand, when HNE diffuses out 
from membranes, its concentration is reduced by the surrounding aqueous phase. Moreover, the 
cytosolic HNE-metabolizing enzymes destroy HNE produced in excess so that the steady-state HNE 
concentration into the cells is reached quickly, ranging from 0.07 µM to 2.8 µM [13,17]. 
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3. Role of ROS and HNE in the Hallmarks of Cancer 
 
3.1. Regulation of Cell Proliferation 
 
The role of ROS in cell proliferation control has been long studied by several research groups. 
Usually, ROS can elicit a broad spectrum of responses depending on the magnitude of the level and the 
duration of exposure. In general, low levels of ROS are mitogenic and promote cell proliferation, while 
intermediate levels cause transient or permanent cell cycle arrest and induce cell differentiation. High 
levels of ROS are detrimental and induce cell apoptosis or necrosis [42,43]. These actions have been 
ruled out by ROS action, acting as a primary messengers in the intracellular signalling cascades, such 
as the mitogen-activated protein kinases (MAPKs), phosphatidylinositol-3-kinase (PI3K)/Akt pathway, 
phospholipase C-g1 (PLCg1) signalling, protein kinase C, p53 signaling, ataxia-telangiectasia-mutated 
(ATM) kinase, nuclear factor-kappaB (NF-κB) signalling, and Jak/Stat pathway [2,43–45]. The cell 
response depends on the pathway activated by ROS, and that can tend to enhance survival or promote 
cell death. Hence, the battle for survival from cell death is determined by the relative balance among 
the activities regulated, the molecular background of cells and tissues, the location of ROS production, 
the concentration of individual ROS species and the antioxidant concentration in the cells [46]. 
Through distinct signal transduction cascades, ROS can induce the expression of families of heat 
shock proteins, immediate early genes of the bZip family members like c-Jun and c-Fos, hypoxia 
inducible factor, and antioxidative enzymes which help to regulate redox homeostasis, the expression 
of transforming oncoproteins and growth factors [46]. 
As far as it regards the effect of HNE in controlling cell proliferation, the majority of research 
reports indicate that HNE elicits a reduction of cell proliferation. The first experiments were done by 
using cultivated human leukemic cells, which do not contain endogenous HNE, as lipid peroxidation in 
such cells is practically null. When added to such cells, however, HNE disappears within 15–20 min, 
partially due to its binding to cell structures, partially to metabolism. So, it is sometimes necessary to 
continuously repeat the treatment in order to stabilize the effects [47]. With K562 cells, originally 
derived from a human erythroleukemia, HNE was found not only to strongly decrease cell 
proliferation, but also to block the expression of the oncogene c-myc which is highly expressed in 
untreated cells [48]. Similarly, in human HL-60 leukemia cells, 1 µM HNE strongly decreases cell 
proliferation, and, at the same time, blocks the expression of the oncogenes c-myc [47,49]. The 
inhibition of c-myc expression by HNE has also been observed in U937 and ML1 human leukemic 
cells, and in MEL murine erythroleukemic cells [50,51].  
These actions of HNE were transient, but could be stabilized by a continuous supply of 1 µM HNE, 
repeated 10–12 times. Deeper investigations in HL-60 cells showed that the proliferation blockage 
occurred at the level of the G0/G1 stage of the cell cycle. In fact, after HNE treatment, there was a big 
accumulation of cells in this phase and a decrease of S-phase cells. This means that the progression to 
the S phase of the cycle is prevented [52]. Further experiments showed that most of the HNE activity 
on the cell cycle is affected through the inhibition of the cyclin expression, especially of cyclins D2, 
D1, and A [53]. As a consequence, pRB was found hypophosphorylated and the E2F transcription 
factor remained bound to the pRB protein [54]. Moreover, HNE reduced the expression of E2F4 
transcription factor [54].  
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In tumor cells which express wild type p53, such as ML-1 human leukemic cells [50] and SK-N-BE 
human neuroblastoma cells [55], HNE is able to induce p53 expression which, in turn, can regulate 
cell cycle arrest or apoptosis induction.  
In solid tumor cells, such as 7777 and J42 hepatomas, inhibitory effects of HNE on cell 
proliferation are lower, probably due to the presence of a more efficient system removing the 
aldehydes. Indeed, these cells display a very high expression of aldehyde dehydrogenase 3, that is able 
to destroy a large amount of the added aldehyde [56,57]. Its inhibition by antisense oligonucleotide has 
strong inhibitory effects on cell proliferation, suggesting that this aldehyde plays an important role in 
this inhibition [58]. 
In other tumor cell lines, such as human neuroblastoma cells SK-N-BE cells, HNE was also able to 
block proliferation and induce apoptosis [55]. Moreover, HNE increased the expression of the p53 
family members (p53, p63, p73) as well as the expression of the cyclin/CDK inhibitor p21 and the 
proapoptotic Bax. An increase in p53 expression also has been found in germ cells where HNE 
treatment inhibited proliferation [59]. Different research groups demonstrated that HNE inhibited 
proliferation of human colon tumor cells through regulation of the MAPs kinase pathway [60,61] or 
through the PPAR gamma pathway [62]. Moreover, a strong inhibition of cell proliferation was 
reported also in breast cancer cells (MCF7) treated with conjugated linoleic acid (CLA), which 
increases the endogenous levels of HNE [63] and in human osteosarcoma cells treated with HNE [64]. 
Interestingly, the effect of HNE on normal cells proliferation is more variable if not opposite to that 
observed in tumor cells. Concerning the atherogenic role of oxidized low-density lipoprotein and the 
lipid oxidatation products, it has been reported that HNE induced vascular smooth muscle cell 
proliferation [65–66]. More recently, other authors have shown that the proliferation rate of smooth 
muscle cells (SMCs) depends on HNE incubation time and concentration: a prolonged treatment with 
0.1 µM HNE resulted in an increase of cell growth in young SMC but displayed cytotoxicity in aged 
SMCs [67]. In the same cell model Vindis and collaborators [68] demonstrated that short-term 
incubation of SMCs with oxLDLs and HNE induced platelet-derived growth factor receptor (PDGFR) 
β activation, while long-term incubation triggered a desensitization of PDGFR to its own agonist, with 
a progressive inhibition of PDGFR β phosphorylation. These authors concluded that PDGFR-β is a 
target for HNE and its progressive inhibition may contribute to defective SMC proliferation.  
A direct comparison between the HNE effect on the growth of human lymphatic leukemia cells and 
normal human peripheral blood lymphocytes has been done by Semlitsch and collaborators [69], 
which demonstrated that HNE showed a cytotoxic effect and reduced DNA synthesis in lymphatic 
leukemia cells, whereas it did not shown any significant toxicity on normal lymphocytes.  
These data indicate that HNE strongly reduces the proliferation of tumor cells but it increases or 
does not affect proliferation of normal cells in relation to the dose of HNE and the time of exposure. 
This dual effect may be due to the presence of aldehyde metabolizing enzymes or the high antioxidant 
concentration in normal cells.  
 
3.2. .Regulation of Apoptosis 
 
It is well known that ROS induce cell death, including apoptosis. Many antitumor agents, such as 
vinblastine, cisplatin, mitomycin C, doxorubicin, camptothecin, inostamycin, neocarzinostatin and 
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many others exhibit antitumor activity via ROS-dependent activation of apoptotic cell death, 
suggesting potential use of ROS as an antitumor agent [70]. Thus, a unique anticancer strategy named 
"oxidation therapy" has been developed by inducing cytotoxic oxystress for cancer treatment. Both 
death receptor- and mitochondria-mediated apoptosis depend a lot on ROS [71]. Fas ligand (FasL) 
triggers a rapid formation of ROS that mainly derive from NADPH oxidase as an upstream event of 
apoptosis induction. Moreover, FasL-induced ROS mediate the ubiquitination and subsequent 
degradation by proteasome of FLICE inhibitory protein (FLIP) to further enhance Fas activation [72]. 
Several researchers have shown that ROS related apoptosis is processed by the mitochondrial 
pathway, through the activation of p38 [73–75]. It has been demonstrated that ROS-dependent 
activation of MAPKs is crucial for mitochondria-mediated apoptosis [76]. In particular, c-Jun NH2-
teminal kinase is the major signaling molecule mediating the ROS-induced opening of the PT pore 
complex [44]. 
In addition to direct activation of signalling pathways, ROS can promote apoptosis via generation of 
lipid peroxidation products, among them HNE plays an important role. For example, it has been 
demonstrated that polyunsaturated fatty acids (PUFAs) such as arachidonic, linolenic and linoleic 
acids markedly enhance the DNA fragmentation induced by glutamate. Thus the DNA fragmentation 
seems to be mediated by ROS or ROS-mediated lipid peroxidation [76]. Moreover, it has also been 
suggested that lipid peroxidation might proceed not only in plasma membranes but also in the nuclear 
membranes close to chromosomes, due to the loss of membrane integrity in cell membranes consisting 
of phospholipids and thereby may make circumstances suitable for oxygen radicals to attack chromatin 
and DNA [76]. However, more convincing data are provided from the studies about the effects of the 
lipid peroxidation product, HNE, in inducing apoptosis in several cell models. Awasthi and 
collaborators [77] demonstrated that the overexpression of the α class of glutathione-S-transferases 
leads to a lower steady-state level of HNE, and induces resistance to apoptosis initiated by lipid 
peroxidation causing agents such as H2O2, UVA, superoxide anion and pro-oxidant xenobiotics. The 
proapoptotic action of HNE has been directly demonstrated in neuronal cells [78], in vascular smooth 
muscle cells [67] and in lens epithelial cells [79]. Furthermore, the proapoptotic effect of HNE, 
accompanied by an increase in Bax protein, has been demonstrated in SK-N-BE human neuroblastoma 
cells [55] and in CaCo-2 human colon cancer cells [62].  
The mechanisms of HNE-induced apoptosis have been studied also by de Villiers and  
collaborators [80]. These authors found that HNE caused dose-dependent apoptosis in two rat hepatic 
stellate cell lines, HSC-T6 and CFSC-2G cells. Apoptosis in HSC-T6 cells was associated with 
increased mRNA and protein expression of the pro-apoptotic adaptors/regulators FasR, FasL, Bax, and 
caspases-2 and -3. In contrast, CFSC-2G cells showed no changes in FasR, Bax and caspase-3 mRNA 
levels. Other authors studied the mechanisms of the apoptotic response to HNE by analysing MAP 
kinase and caspase activation pathways in 3T3 fibroblasts [81]. HNE induced early activation of JNK 
and p38 proteins but down-regulated the basal activity of ERK-1/2. Moreover, HNE induced the 
release of cytochrome c from mitochondria as well as caspase-9 and caspase-3 activation. 
Overexpression of dominant negative c-Jun and JNK1 in 3T3 fibroblasts prevented HNE-induced 
apoptosis, which indicated a role for the JNK-c-Jun/AP-1 pathway. These data confirm previous 
observations from Biasi and collaborators [82] who found that c-Jun N-terminal kinase upregulation 
was a key event in the proapoptotic interaction between transforming growth factor-β1 and 4-
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hydroxynonenal in colon mucosa [82]. Exposure of vascular smooth muscle cells to HNE showed 
augmented apoptotic changes in a concentration-dependent manner and was associated with an 
increased production of ROS. These authors conclude that mitochondrial dysfunction plays a key role 
in mediating HNE-induced vascular smooth muscle cell apoptosis through an increased mitochondrial 
production of ROS [67]. The involvement of HNE-mediated apoptosis in the oxidative damage of 
neural cells has been suggested by several authors [78,83] by analyzing the role of HNE in cell death 
resulting from β-amyloid exposure. These authors showed that HNE treatment of neuronal cells 
induced dose-dependent death and caspase activation which were blocked by inhibition of caspases.  
An indirect demonstration of the ability of HNE to induce apoptosis is represented by results 
obtained by lowering the intracellular concentration of HNE in cells transfected with enzymes 
involved in HNE metabolism. For example, the over-expression of GSTA4-4 or GST5.8, which 
detoxify HNE, inhibits apoptosis induced by the xantine/xanthine oxidase, H2O2, UV and  
doxorubicin [84]. HL-60 cells also acquire resistance to apoptosis induced by 20 µM HNE when 
transfected with GSTA4-4n [85]. On the contrary, increased concentration of HNE, obtained by 
inhibiting RalBP1-mediated transport of GS-HNE, leads to apoptosis in cells of various origin even in 
the absence of any stressor [86,90]. In conclusion, several reports, by showing a role for HNE in 
apoptosis induction, demonstrate the involvement of lipid peroxidation in this process. 
 
3.3. Regulation of Replicative Potential of Cells  
 
It is widely accepted that the replicative potential of the cell is limited. After a certain number of 
division cells start the senescence or permanent irreversible replication arrest [91]. This status occurs 
when the cell encounters sublethal levels of certain stresses, such as elevation of ROS, oncogene 
overexpression, or irradiation. It has been shown that treatment with exogenous reactive oxygen 
species, such as H2O2, induces premature senescence [92,93]. In fact, nearly all stresses that induce 
senescence are thought to increase intracellular ROS [94]. It was broadly believed that high oxygen 
levels (hyperoxia) should elevate intracellular ROS production. Indeed, hyperoxia can force human 
fibroblasts [95] and human articular cartilage chondrocytes [96] to arrest in a senescent-like-fashion. 
Over-expression of antioxidant genes such as superoxide dismutase or catalase and the maintenance of 
cell culture in a low oxygen environment extend lifespan [97]. Controversial data about the role played 
by ROS were obtained in human lung fibroblasts cultured under hypoxia [98]. In this condition ROS 
levels increase, rather than decrease, paralleling an increase of replicative life span.  
Senescence is accompanied by telomere loss. Telomeres correspond to the ends of eukaryotic 
chromosomes and are specialized structures containing unique (TTAGGG)n repeats, protecting the 
chromosomes from DNA degradation, end to end fusions, rearrangements, and chromosome loss [99]. 
The number of telomere repeats decreases (by 50–200 nucleotides/cell division) during aging of 
normal somatic cells [100] and it has been proposed to be a mitotic clock marking progression of a cell 
toward the end of its replicative lifespan. Synthesis and maintenance of telomeric repeats are mediated 
by a specialized enzyme, known as telomerase [101], a ribonucleoprotein complex which contains a 
catalytic subunit, the human telomerase reverse transcriptase (hTERT) and a small integral RNA 
component (hTR), utilized as a template for the synthesis of the dGT-rich strand of telomeres [101]. 
Inhibition of telomerase activity leads the cells to senescence [102]. Although normal somatic cells do 
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not express telomerase, immortalized cells such as tumor cells express this enzyme [103, 104]. For this 
reason, telomerase activity and hTERT expression have become new targets for tumor treatments. The 
effect of ROS on telomerase activity is controversial. In vascular smooth muscle cells, senescence is 
accelerate by oxidative stress-induced DNA damage accompanied by the inhibition of telomerase and 
marked telomere shortening [105]. On the other hand, it has been recently reported that oxidative 
stress enhanced the malignant potential of human hepatocellular carcinoma through the activation of 
telomerase [106]. In this field, the demonstration that, in hypoxic conditions, ROS activate the 
transcription factor hypoxia inducible factor (HIF), which induces transcription of the hTERT gene [98] 
further indicates that the role of ROS in telomerase control is not univocal.  
On the contrary, our research group demonstrated that HNE strongly inhibited the activity of 
telomerase and the expression of its catalytic subunit hTERT in three different human leukemic cell 
lines, HL-60, U 937 and ML-1 [50]. Telomerase activity can be regulated by the reduced glutathione 
(GSH), the natural scavenger of HNE. Indeed, Borras and collaborators demonstrated that intracellular 
GSH content paralleled telomerase activity in 3T3 fibroblast [107]. However, in other cells, such as 
colon carcinoma Caco-2 cells GSH depletion by HNE can only partially contribute to the down-
regulation of telomerase activity [108]. 
The major mechanism by which this aldehyde exerts the inhibition of telomerase activity seems to 
be the regulation of transcriptional control of the hTERT gene, by modulating the expression of 
transcription factors belonging to the Myc/Mad/Max network. The hTERT promoter contains several 
binding sites for transcription factors, including activators (c-Myc, Sp-1) and repressors (Mad1) [109] 
and we studied the expression of these proteins and their binding to the hTERT promoter after HNE 
treatment. Myc protein forms dimers with the Max protein that bind to the 5’-CACGTG-3’ sequence 
(E-box) in promoters and transactivate target genes. Max also forms dimers with the Mad family 
proteins and all complexes bind to the same E-box, having an inhibitory function [110]. HNE was able 
to inhibit c-Myc and induce Mad-1 expression in all of the three cell lines. The E-box binding studies 
demonstrated that in HNE-treated HL-60 cells there is a decrease in Myc binding complexes and an 
increase in Mad-1 binding complexes. This modulation could contribute to the switch from  
c-Myc/Max to Mad1/Max occurring at the E-box of the hTERT promoter. This inhibitory mechanism 
of hTERT expression and, as a consequence, of telomerase activity by HNE has been confirmed in 
CaCo-2 human colon cancer cells also [108]. 
 
3.4. Regulation of Angiogenesis 
 
In addition to the genetic and epigenetic changes that occur during transformation, another discrete 
step is required to allow tumor propagation and progression: the induction of a tumor vasculature, 
termed the “angiogenic switch” [111]. Angiogenesis is orchestrated by a variety of activators and 
inhibitors and, during the “angiogenic switch”, the predominant angiogenic factors can activate 
quiescent endothelial cells, thus stimulating them to initiate migration, proliferation and organisation in 
tubular structure. Activators of endothelial-cell proliferation and migration are mainly receptor tyrosine 
kinase ligands, such as vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), 
platelet-derived growth factor (PDGF). A prototypical angiogenesis inhibitor is thrombospondin-1 and 
many other molecules have been identified, such as angiostatin and endostatin [111]. The importance 
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of the angiogenic program in controlling tumor growth is underlined by antiangiogenic gene therapy as 
a new therapeutic approach to the treatment of cancer patients [112]. 
A large body of evidence demonstrate the pro-angiogenic role of ROS and results have been 
reviewed by several authors [12,46,113–115]. Exogenous ROS stimulate induction of VEGF, promote 
cell proliferation and migration [116–119], cytoskeletal reorganization [120] and tubular 
morphogenesis [118,121] in ECs. Moreover, ROS are involved in the production of pro-angiogenetic 
factors in different cell types, both of normal and tumoral origin [46,113,122,123]. As previously 
reported, the major source of ROS is aerobic respiration in the mitochondria. In tumor cells and in 
endothelial cells, ROS can also be generated by the NADPH-oxidase [113,124]. Modulation of the 
activity of this enzyme affects cell growth and angiogenesis in various experimental models [125–127]. 
For example, the transfection of NIH 3T3 cells with the Nox1 gene, a homolog of gp91phox, the 
catalytic subunit of the NADPH-oxidase, renders them capable of forming well vascularized tumors, 
whereas the parent cells form microscopic dormant tumors that are poorly vascularized. Similarly, 
Nox1 expression converts DU-145 prostate epithelial cells from weak to strong tumorigenic potential, 
with a corresponding increase in tumor vascularity, pointing out the generality of the angiogenic effect 
of Nox1 [128]. 
The angiogenic property of HNE is under investigation, but literature is still poor and conflicting 
results have been reported. HNE, at concentrations of 1.0 and 2.5 µM, significantly stimulated rat 
aortic smooth muscle cell growth and PDFG production [129]. Ayalasomayajula and Kompella reported 
an increase of VEGF expression in human retinal pigment epithelial cells after treatment with 1 µM 
HNE [130]. Moreover VEGF receptor 1 expression was induced in a dose-response manner in myeloid 
cells treated with 15 and 60 µM HNE [122]. However, the anti-angiogenic properties were recently 
demonstrated by Stagos and collaborators in human bone marrow endothelial cells (HBMEC) [131]. 
These authors demonstrated that 5 and 10 µM HNE were able to inhibit the tube formation of HBMEC 
cells. In an attempt to elucidate the mechanism, they demonstrated that this inhibition occurs at least in 
part via HNE-induced expression of chondromodulin-I (CHM-I), a protein with well-known anti-
angiogenetic properties [131]. The anti-angiogenic property of HNE is also sustained by our recent 
findings on microRNA (miRNA) [132], a class of conserved non-coding small RNAs, which regulate 
gene expression by translation repression of coding mRNAs [132]. HNE, indeed, is able to modulate 
the expression of ten miRNAs in HL-60 human leukemic cells. Among them, we observed the down-
regulation of miR-378 [132], which has been demonstrated to enhance cell survival, tumor growth, and 
angiogenesis in the human glioblastoma U-87 cell line [134], through repression of the expression of 
two tumor suppressors, Sufu and Fus-1. In accordance to these results, we demonstrated that HNE is 
also able to up-regulate Sufu expression in HL-60 cells after HNE-treatment [132]. 
 
3.5. Regulation of Cell Adhesion, Tumor Invasion and Metastasis 
 
Tumor invasion and metastasis, responsible for most cancer death in humans, consist in a series of 
steps that include shedding of cells from a primary tumor into the circulation, survival of the cells in 
the circulation, arrest in a new organ, extravasation into the surrounding tissue, initiation and 
maintenance of growth, and vascularization of the metastatic tumor. All of these processes are 
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regulated by multiple factors and must be successfully completed to permit the outgrowth of metastatic 
tumors in the new microenvironment [135]. 
The cellular disengagement requires the modulation of expression of cell-cell adhesion molecules at 
adherent junctions [136], such as E-cadherin, which, on its cytoplasmic face, organizes the actin 
cytoskeleton via its association with β-catenin, a transcription factor involved in signalling via the Wnt 
pathway [136]. 
Integrins perform essential roles in cell adhesion to the extracellular matrix (ECM). Evidence 
suggests that the interference with integrin-mediated adhesion can impair tumor metastasis [137]. A 
role for the Focal adhesion kinase (FAK) on cell interactions with the extracellular matrix in tumors 
has been recently demonstrated [138]. This kinase maintains a role in adhesion, cell spreading and 
migration and cell proliferation and is up-regulated in metastatic tumors [139]. 
The ECM-degrading enzymes, such as matrix metalloproteinases (MMPs) play also an important 
role in mediating tumor cell invasion. The general belief is that overexpression of a specific MMP, 
either by tumor cells or the surrounding stroma, is pro-tumorigenic [140]. However, there is an 
increasing amount of literature demonstrating that the expression of certain MMPs, either at the 
primary or the metastatic site, provides a beneficial and protective effect in multiple stages of cancer 
progression [141]. Similarly, the tissue inhibitors of metalloproteinases (TIMPs) are intriguing 
molecules that have both pro and antitumorigenic effects [142]. 
The extravasation process of circulating cancer cells is also a key step in metastasis which has 
features similar to the inflammatory recruitment of leukocytes. Indeed, this process is regulated by cell 
adhesion molecules (CAMs), such as intercellular cell adhesion molecule-1 (ICAM-1), vascular 
endothelial cell adhesion molecule-1 (VCAM-1), E-selectin, and P-selectin [143]. These molecules are 
usually up-regulated in tumor progression.  
It has been reported, in addition to regulating tumor growth, survival and angiogenesis, that ROS 
also control the formation of tumor metastases [106]. In many types of tumors including prostate 
cancer, melanoma and breast cancer, the increased metastatic ability of tumor cells is positively related 
to their intracellular ROS level [106]. Exogenously administration of ROS would enhance certain 
stages of metastasis [144], while anti-oxidant treatment could attenuate metastatic progress [145]. 
Recently, Ishikawa and collaborators [146] have provided direct evidence to confirm the causative 
relationship between ROS and tumor metastasis. After being replaced with mitochondrial DNA 
(mtDNA) derived from a higly metastatic mouse tumor cell line, an originally poorly metastatic cell 
line acquires the metastatic potential. The transferred mtDNA contains mutations producing a 
deficiency in respiratory complex I activity and are associated with overproduction of ROS. 
Pretreatment of the highly metastatic tumor cells with ROS scavengers suppressed their metastatic 
potential in mice [146]. ROS also participate in the loss of cell-cell-interaction, inhibiting the  
E-cadherin expression or disruption of the cadherin-β-catenin complex [147–149]. 
Besides cell-cell-interaction, the adhesion of cells in the extracellular matrix as mediated by 
integrins is of importance for the stability of tumor tissue [150]. ROS can have a different effect on 
integrins, due to their dual role. For example, it has been found that ROS lead to a significant reduction 
of the αvß3 -integrin [151] in sarcomas, while ROS lead to up-regulation of a set of integrin family 
members (integrin α2, α6, and β3) in mammary epithelial cells [147]. Oxidative stress is also able to 
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activate FAK by inducing its autphosphorylation in tyrosine and this could explain the role of ROS in 
mediating cell spreading and migration [152].  
Oxidative stress may induce tumor cell migration and invasion through the activation of MMPs, 
also. ROS can activate MMPs, such as MMP-2, probably though the reaction of ROS with thiol groups 
in the protease catalytic domain [153]. Additionally, ROS are able to up-regulate the expression of 
several MMPs (MMP-1, MMP-3, MMP-9, MMP-10, MMP-13) [154]. The pathway proposed in this 
up-regulation seems to involve Ras or the MAPK family member ERK1/2, p38 and JNK [155]. The 
direct activation of the Ras effector ERK1/2 leads to the induction of the Ets transcription factor and 
JNK-regulated the transcription factors Jun and Fos which form the AP-1 complex. Both AP-1 and Ets 
regulate MMP expression [154,156]. Additionally, other redox-sensitive transcription factors, such as 
NF-κB can regulate MMPs expression [154]. 
According to these findings, MMP inhibitors and TIMPS, are down-regulated by ROS [157], 
leading to an increase of the metastatic potential of tumors. In some cases, ROS do not induce TIMP 
expression, while MMPs activity is enhanced, but in any case the balance between MMPs and TIMPs 
is shifted towards MMPs, with a metastatic significance [158,159] 
However, results in this field are controversial. Indeed, the MMP-2 and 9 activities in the  
DS-sarcoma cell line were markedly reduced immediately after ROS-inducing treatment [151]. 
Moreover the Rac-dependent induction of ROS is able to inhibit TIMP-1 expression in renal 
carcinoma cells and other different tumor cell lines [160], inhibiting matrigel invasion [161]. 
ROS have been involved in the extravasation process. For example, oxidative stress regulates the 
expression of cell surface protein ICAM-1 in endothelial and epithelial cells, most likely due to the 
activation of NF-κB [162]. 
The effects of HNE on cell adhesion, invasion and metastasis are fragmentary and ambiguous. An 
anti-metastatic and anti-invasive role of HNE has been demonstrated by our research group, since this 
aldehyde inhibits Notch expression [163], a transmembrane receptor involved in neoplastic epithelial-
mesenchymal transition  [164], which promotes E-cadherin down-regulation [165]. 
Usatyuk and collaborators [166] demonstrated that HNE increases the vascular endothelial 
permeability, by affecting focal adhesion, adherence, and tight junction proteins. Indeed, exposure of 
bovine lung microvascular endothelial cells (BLMVECs) to HNE induced reactive oxygen species 
generation and altered cell-cell adhesion as measured by transendothelial electrical resistance. In 
particular HNE supresses tyrosine phosphorylation of FAK, and caused the redistribution of catenin, 
paxillin and VE-cadherin [166]. Moreover, HNE caused a decrease in surface integrin levels, without 
altering total α5 and β3 integrins. The formation of HNE-derived Michael adducts with specific 
proteins seems to be the mechanism by which this aldehyde is able to affect cell-cell adhesion since 
HNE-adducts were observed in FAK, E-cadherin, β-catenin and α5 and β3 integrins[166]. Similar 
results were obtained in human osteosarcoma cells, where HNE was able to down-regulate FAK 
expression [167]. Moreover, these authors reported an increase of α5β1 integrin expression after HNE-
treatment [167], which may be involved in the reduction of proliferation and metastatic ability [168,169]. 
The effect of HNE on MMPs and TIMPs expression are differentially modulated by HNE, 
depending on cell type. In normal cells, such as vascular smooth muscle cells, MMP-2 is enhanced by 
HNE via mitochondrial ROS-mediated activation of the Akt/NF-κB signaling pathways [170]. 
Consistently, HNE also elicited the production of MMP-1 in human coronary smooth muscle cells, 
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with the involvement of PDGFR-β and ERK1/2 [171]. In osteoarthritic (OA) synovial cells, HNE 
induces MMP-13 synthesis and activity but in contrast inhibits type II collagen and TIMP-1 synthesis 
playing a role in OA cartilage degradation [172]. 
In contrast with these findings, it has been shown that HNE did not significantly affect expression 
of MMP-1 and MMP-2 while it up-regulated of TIMP-1 expression in human hepatic stellate cells, as 
pro-fibrogenic stimulus [173]. 
HNE effects on cell adhesion molecules of endothelium are generally convergent, since several 
authors demonstrated the inhibitory role of this aldehyde on the endothelial response. For example, 
HNE caused a dose-dependent decrease in production of both interleukin-8 (IL-8) and intercellular 
adhesion molecule-1 (ICAM-1) in HUVEC [174] and, in human aortic endothelial cells, HNE 
dramatically inhibited the expression of several adhesion molecules, such as ICAM-1, VCAM-1 and 
E-selectin, induced by inflammatory stimuli, accompanied by a significant reduction of NF-κB 
activation [175].  
Recently we demonstrated that HNE reduced adhesion of HL-60 cells to endothelial cells 
(HUVECs) [176]. The mechanism proposed involves the formation of HNE-α-enolase adduct(s) in 
HL-60 human leukemic cells, impairing the plasminogen-binding activity of α-enolase.  
 
3.6. Regulation of Genomic Instability-DNA Repair 
 
An unstable genome is a hallmark feature of nearly all tumors; this instability first appears early in 
tumor progression, and can take several forms [177]. Intrachromosomal genomic instability in cancer 
arises from several mechanisms: increased rates of damage, deficiencies in the DNA repair enzymes 
and checkpoint defects which fail to halt the cell cycle until repair. Several of the hallmarks of cancer 
described above are associated with genomic instability. For instance, the ability to evade apoptosis 
through alterations in p53 [178, 179] and Bcl-2 [180], as well as shortened telomere length [181], are 
all associated with increased genomic instability in breast cancers. This instability underlies the vast 
majority of genomic events. Chromosomal instability at the whole chromosome level arises from 
inappropriate segregation, recombination and the like, and generates relatively few events [177]. 
Inefficient DNA repair is a well documented cause for the generation of genomic instability in 
cancer [182]. For instance, genetic disorders such as Xeroderma pigementosum provide clear examples 
of how defects in these genes can contribute to genomic instability and malignancy [182, 183]. 
Damage repair deals with single events through base excision repair (BER), nucleotide excision repair 
(NER), or mismatch repair (MMR). Specialized genes exist for various forms of repair optimized for 
the particular type of damage [184]. 
The major mechanism that cells use to repair oxidative damage lesions, seems to be the BER [185], 
while the HNE-DNA adducts seems to be repaired preferentially by NER [30]. 
The role of ROS and HNE in contributing to genetic instability has not yet been clarified and a 
double effect can arise from experimental evidences. As previously reported, both ROS and HNE 
induced DNA mutations through the breakdown of DNA, oxidation of DNA bases or adducts 
formation. ROS induced mutations in DNA can be prevented by a DNA MMR system that maintains 
sequence fidelity during DNA replication. Key members of the MMR system include hMSH2 and 
hMSH6 [186]. Both ROS and HNE can interfere with genomic instability and DNA repair. It has been 
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demonstrated that oxidative stress interferes with repair of single base mutations, by inhibiting hMSH6 
[187] and HNE could contribute to generate DNA instability by inhibiting, in human cells, the 
nucleotide excision repair, the most important process able to repair DNA-adducts [30]. On the other 
hand, ROS and HNE induce the expression of p53, the guardian of the genome which is able to trans 
activate genes whose products arrest cell cycle (p21), induce DNA repair (gadd 45) or promote 
apoptosis (Bax) [188].  
 
4. Concluding Remarks 
 
In this review we summarised the different effects displayed by ROS and HNE in controlling 
carcinogenesis, cell proliferation and tumor progression and invasion. In all these areas the effects of 
ROS and HNE are different, in relation to doses, cell type and molecular pathway employed.  
Moreover, for both ROS and HNE, the majority of experiments were performed “in vitro” and the 
lack of “in vivo” evidence limits the possibility for a real evaluation of their effects on tumor 
development. Indeed, in tumor tissue the presence of ROS, as well as of lipid peroxidation products, 
depends  not only on their concentration in each tumor cell, that by virtue of the tumor heterogeneity, 
can be highly variable, but also on their concentration in surrounding tissue that may affect the tumor 
cell response. Finally, it must be underlined that both ROS and HNE are physiologically present in the 
cells and they play an important role in cell life. For this reason, it is very important to clarify the risks 
and benefits of a perturbation of ROS and HNE levels in tumor cells and in this field there is much 
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